Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium

Heart. 2001 Jul;86(1):45-51. doi: 10.1136/heart.86.1.45.

Abstract

Objective: To define the effects of beta(2) adrenergic receptor stimulation on ventricular repolarisation in vivo.

Design: Prospective study.

Setting: Tertiary referral centre.

Patients: 85 patients with coronary artery disease and 22 normal controls.

Interventions: Intravenous and intracoronary salbutamol (a beta(2) adrenergic receptor selective agonist; 10-30 microg/min and 1-10 microg/min), and intravenous isoprenaline (a mixed beta(1)/beta(2) adrenergic receptor agonist; 1-5 microg/min), infused during fixed atrial pacing.

Main outcome measures: QT intervals, QT dispersion, monophasic action potential duration.

Results: In patients with coronary artery disease, salbutamol decreased QT(onset) and QT(peak) but increased QT(end) duration; QT(onset)-QT(peak) and QT(peak)-QT(end) intervals increased, resulting in T wave prolongation (mean (SEM): 201 (2) ms to 233 (2) ms; p < 0.01). There was a large increase in dispersion of QT(onset), QT(peak), and QT(end) which was more pronounced in patients with coronary artery disease-for example, QT(end) dispersion: 50 (2) ms baseline v 98 (4) ms salbutamol (controls), and 70 (1) ms baseline v 108 (3) ms salbutamol (coronary artery disease); p < 0.001. Similar responses were obtained with isoprenaline. Monophasic action potential duration at 90% repolarisation shortened during intracoronary infusion of salbutamol, from 278 (4.1) ms to 257 (3.8) ms (p < 0.05).

Conclusions: beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium. The increase in dispersion of repolarisation provides a mechanism whereby catecholamines acting through this receptor subtype may trigger ventricular arrhythmias.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Action Potentials / drug effects
  • Adrenergic beta-Agonists / pharmacology*
  • Albuterol / pharmacology*
  • Analysis of Variance
  • Case-Control Studies
  • Coronary Disease / metabolism*
  • Coronary Disease / physiopathology
  • Electrocardiography / drug effects
  • Female
  • Humans
  • Infusions, Intravenous
  • Isoproterenol / pharmacology*
  • Male
  • Middle Aged
  • Myocardium / metabolism*
  • Prospective Studies
  • Receptors, Adrenergic, beta / metabolism*
  • Stimulation, Chemical

Substances

  • Adrenergic beta-Agonists
  • Receptors, Adrenergic, beta
  • Isoproterenol
  • Albuterol